News

BEAM receives $1.84 million NIH grant to improve preventative screening for opioid use disorder in partnership with UVA Health

BEAM Diagnostics, Inc. (BEAM), a behavioral health company delivering digital assessments to improve patient-centered healthcare – has been awarded a $1.84 million grant from the National Institutes of Health (NIH) to commercialize its pioneering technology, improving and increasing proactive assessment of opioid use disorder in outpatient medical clinics.

BEAM’s proprietary technology, Beacon-OUD, is a digital screening tool that quickly and accurately determines a patient’s risk of opioid use disorder without asking stigmatizing questions. In a clinical study, providers viewed Beacon-OUD as a means to encourage patients to be a part of their treatment, provide education, and build provider-patient rapport.

“We care for patients with chronic pain who require opioids, which carry a risk of addiction. We plan to use Beacon-OUD to help us identify our patients who are at higher risk for opioid use disorder and provide better care,” said John Day Gazewood, MD, MSPH, FAAFP, Harrison Medical Teaching Associate Professor of Family Practice, Residency Program Director, and Vice Chair of UVA Health’s Department of Family Medicine.

The 24-month Phase II SBIR grant from the NIH’s National Institute on Drug Abuse (NIDA) builds upon previous validation work, allowing BEAM to finalize the development and implementation of Beacon-OUD into primary care clinics as a digital assessment for providers. In partnership with UVA Health, BEAM will begin interfacing with UVA Health’s electronic medical record system, making the tool readily accessible to providers and patients.

“Behavioral health screenings should be as easy and routine as taking your blood pressure,” said Dr. Sarah Snider, BEAM Co-Founder & Chief Executive Officer. “The NIH funding and our partnership with UVA Health will help make that a reality. By demonstrating how impactful preventative screening can be to patients and providers, this work takes us closer to making proactive, patient-centered healthcare the industry standard.”

Beacon-OUD will be accessible on BEAM’s digital assessment platform, Beacon, which can be administered anywhere, simplifying assessment delivery. Beacon and its library of behavioral health assessments will be available to large healthcare systems and smaller practices alike through its standalone web application and EMR-application marketplaces. BEAM plans to capture the digital behavioral assessment market by expanding its offerings with data-driven results and seamless integration into healthcare workflows and digital health solutions.

Note: “Research reported in this publication was supported by the National Institute on Drug Abuse of the National Institutes of Health under Award Number R44DA048689. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Learn more here.

Recent News

07/01/2025

ISOThrive Announces Promising Phase 2 Interim Data for Novel Heartburn Treatment and Appoints Pharma Veteran Mike Walther as Chief Strategy Officer

ISOThrive Inc., a clinical-stage biopharmaceutical company, announced interim results from a Phase 2 study of its lead candidate, ISOT-101, for treatment of Non-Erosive Reflux Disease (NERD). The data showed positive trends in addressing heartburn frequency and symptom severity among proton pump inhibitor (PPI) partial-responders (PR), a patient population with major unmet medical need. These positive

07/01/2025

Gary Lowenthal Joins Focused Ultrasound Foundation’s Council

The Focused Ultrasound Foundation is pleased to welcome Gary Lowenthal to its Council, a dedicated group of goodwill ambassadors who work closely with the Board of Directors and staff to provide advice and assist with raising funds and building awareness. Mr. Lowenthal is a retired educator, entrepreneur, and executive with a career spanning education, international service,

06/25/2025

Liquet Medical Closes Oversubscribed Seed Round to Launch Pilot Study Evaluating Real-Time Hemodynamic Monitoring

Liquet Medical, a clinical-stage medical device company developing the Versus™ Catheter — a first-of-its-kind dual-tipped catheter system cleared by the FDA for controlled and selective infusion of fluids into the pulmonary vasculature and hemodynamic monitoring — announced the successful and oversubscribed close of its Seed funding round, which officially closed in May 2025. The capital